Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project - 09/12/17

Paul L. Hess, MD, MHS ^{a, b, ⁎} , Kevin Kennedy, MS ^c, Michael Cowherd, MD ^b, Salim S. Virani, MD, PhD ^d, Frederick A. Masoudi, MD, MSPH ^b, Ann Marie Navar, MD, PhD ^e, Robert W. Yeh, MD, MSc ^f, P. Michael Ho, MD, PhD ^{a, b}, Thomas M. Maddox, MD, MSc ^g

^a VA Eastern Colorado Health Care System, Denver, CO 

^b University of Colorado School of Medicine, Denver, CO 

^c Mid-America Heart Institute, Kansas City, MO 

^d Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX 

^e Duke Clinical Research Institute, Durham, NC 

^f Beth Israel Deaconess Medical Center, Boston, MA 

^g Washington University School of Medicine, St Louis, MO 

^⁎Reprint requests: Paul L. Hess, MD, MHS, Cardiology Section (111B), Eastern Colorado Health Care System, 1055 Clermont St, Denver, CO 80220.Cardiology Section (111B), Eastern Colorado Health Care System1055 Clermont StDenverCO80220

Le texte complet de cet article est disponible en PDF.